Ionis Pharmaceuticals, Inc.

BMV:IONS * Stock Report

Market Cap: Mex$115.3b

Ionis Pharmaceuticals Valuation

Is IONS * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IONS * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IONS * (MX$743) is trading below our estimate of fair value (MX$796.57)

Significantly Below Fair Value: IONS * is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IONS *?

Key metric: As IONS * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IONS *. This is calculated by dividing IONS *'s market cap by their current revenue.
What is IONS *'s PS Ratio?
PS Ratio7.1x
SalesUS$803.07m
Market CapUS$5.67b

Price to Sales Ratio vs Peers

How does IONS *'s PS Ratio compare to its peers?

The above table shows the PS ratio for IONS * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.7x
LAB B Genomma Lab Internacional. de
1.4x9.7%Mex$24.2b
6990 Sichuan Kelun-Biotech Biopharmaceutical
19.2x23.9%HK$38.3b
600161 Beijing Tiantan Biological Products
7.9x19.6%CN¥41.3b
002007 Hualan Biological Engineering
6.5x16.7%CN¥31.8b
IONS * Ionis Pharmaceuticals
7.1x22.1%Mex$5.7b

Price-To-Sales vs Peers: IONS * is good value based on its Price-To-Sales Ratio (7.1x) compared to the peer average (8.7x).

Price to Sales Ratio vs Industry

How does IONS *'s PS Ratio compare vs other companies in the Global Biotechs Industry?

233 CompaniesPrice / SalesEstimated GrowthMarket Cap
No. of Companies233PS01224364860+
233 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IONS * is good value based on its Price-To-Sales Ratio (7.1x) compared to the Global Biotechs industry average (9.2x).

Price to Sales Ratio vs Fair Ratio

What is IONS *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IONS * PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate IONS *'s Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IONS * forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
Mex$1,231.66
0%
17.2%Mex$1,565.73Mex$742.72n/a25
Dec ’25n/a
Mex$1,261.74
0%
17.0%Mex$1,588.57Mex$762.84n/a25
Nov ’25n/a
Mex$1,208.41
0%
16.3%Mex$1,590.25Mex$717.55n/a25
Oct ’25n/a
Mex$1,258.97
0%
16.2%Mex$1,647.27Mex$743.28n/a25
Sep ’25n/a
Mex$1,218.45
0%
16.0%Mex$1,588.17Mex$716.61n/a25
Aug ’25n/a
Mex$1,153.16
0%
18.4%Mex$1,539.31Mex$619.48n/a25
Jul ’25n/a
Mex$1,077.33
0%
18.8%Mex$1,509.75Mex$607.58n/a23
Jun ’25n/a
Mex$979.21
0%
19.8%Mex$1,385.62Mex$557.63n/a23
May ’25n/a
Mex$995.62
0%
20.5%Mex$1,455.78Mex$496.68n/a24
Apr ’25n/a
Mex$957.55
0%
24.2%Mex$1,435.06Mex$489.61n/a22
Mar ’25n/a
Mex$964.08
0%
23.8%Mex$1,453.00Mex$495.73n/a22
Feb ’25n/a
Mex$960.55
0%
23.9%Mex$1,452.35Mex$478.42n/a22
Jan ’25n/a
Mex$932.20
0%
24.8%Mex$1,444.03Mex$475.68n/a22
Dec ’24n/a
Mex$941.55
0%
25.6%Mex$1,471.66Mex$484.78n/a22
Nov ’24n/a
Mex$961.57
0%
28.9%Mex$1,588.71Mex$451.34n/a22
Oct ’24n/a
Mex$914.63
0%
31.0%Mex$1,544.86Mex$438.88n/a22
Sep ’24n/a
Mex$868.51
0%
33.0%Mex$1,499.73Mex$426.06n/a21
Aug ’24n/a
Mex$857.29
0%
32.5%Mex$1,473.51Mex$401.87n/a21
Jul ’24n/a
Mex$856.23
0%
33.5%Mex$1,506.63Mex$445.14n/a21
Jun ’24n/a
Mex$870.67
0%
33.6%Mex$1,545.28Mex$456.56n/a21
May ’24n/a
Mex$879.50
0%
36.6%Mex$1,660.37Mex$433.14n/a20
Apr ’24n/a
Mex$903.30
0%
36.8%Mex$1,713.13Mex$446.90n/a20
Mar ’24n/a
Mex$920.68
0%
35.2%Mex$1,693.71Mex$441.84n/a20
Feb ’24n/a
Mex$962.10
0%
33.9%Mex$1,732.31Mex$451.91n/a20
Jan ’24n/a
Mex$1,003.67
0%
33.6%Mex$1,807.32Mex$471.48n/a21
Dec ’23n/a
Mex$1,000.25
0%
32.8%Mex$1,774.69Mex$462.96n/a21

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 09:53
End of Day Share Price 2024/12/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ionis Pharmaceuticals, Inc. is covered by 46 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Huidong WangBarclays
James BirchenoughBarclays